Enrique Gallardo, MD, discusses the final overall survival (OS) results from the EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in patients with metastatic castration-resistant prostate cancer.
Enrique Gallardo, MD
Advertisement
Articles by Enrique Gallardo, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
The ArteraAI Prostate Test: What It Is and How It Works
2
HHS requests testosterone therapy label updates, citing new safety data
3
Retrospective study suggests differences in OAB therapy persistence among older adults
4
Unmet needs and emerging solutions in MRI-guided prostate cancer care
5